Panacea Biotec supplies 2nd component of Sputnik V vaccine in India
New Delhi: The Russian Direct Investment Fund (RDIF) and Panacea Biotec Ltd., have announced the supply of the 1 st shipment out of 1 million doses of the second component (human adenovirus serotype 5) of the Russian Sputnik V coronavirus vaccine manufactured by Panacea Biotec for sale in India.
This is the first batch of the second component produced and supplied by the Company in India. Doses of the second component of Sputnik V have been manufactured at the Panacea Biotec's state of the art vaccine manufacturing facility in Himachal Pradesh. The Company received necessary clearance from Central Drug Laboratories (CDL), Kasauli on August 31, 2021.
Full-scale production of Spuntik V started at Panacea Biotec's facilities this summer. Facilities comply with GMP standards and are prequalified by WHO. The batch will be distributed in India through a partner of RDIF and Panacea Biotec – Dr. Reddy's Laboratories. To date Sputnik V has been authorized in 70 countries with total population of over 4 billion people.
Dr. Rajesh Jain, Managing Director of Panacea Biotec, said: "Panacea Biotec is pleased to have successfully produced and dispatched the first batch of Component II (Ad5) of Sputnik V vaccine. More batches are currently under production at our manufacturing facility in Himachal Pradesh."